8/24/2010

Drugmaker Lupin expects sales in emerging markets to equal sales in the U.S. and Japan, combined, by 2018. The company plans to expand operations in Brazil and Mexico, where it sees opportunity in gynecology, cardiology, oral contraceptives and biotechnology markets.

Related Summaries